Table:
No.	%
Patients
Treated	39	100.0
Evaluable for response	36	92.3
Age
Median (years)	51.3
Range	41.2 – 64.1
ECOG performance status
0	3	7.7
1	27	69.2
2	9	23.1
Site(s) of metastatic lesion(s)*
Lung	27	69.2
Liver	9	23.1
Lymph node	15	38.5
Soft tissue	3	7.7
Bone	24	61.5
Brain	3	7.7
Response to prior anthracyclines
Primary resistant	24	61.5
Secondary resistant	15	38.5
Interval from the cessation of last chemotherapy
Median (months)	4.1
Range	1.0 – 11.2
No. of prior chemotherapy regimens
Hormonal therapy (total)	20	51.3
1	9	23.1
2	21	53.8
3 or more	9	23.1
Characteristics of prior chemotherapy†
CMF	24
CAF	15
FEC	9
VE	21
High-dose therapy with stem cell rescue	6
AT	3

Interpret the illustration as Markdown format.

|  | No. | % | 
 | --- | --- | --- | 
 | Patients |  |  | 
 | Treated | 39 | 100.0 | 
 | Evaluable for response | 36 | 92.3 | 
 | Age |  |  | 
 | Median (years) | 51.3 |  | 
 | Range | 41.2 – 64.1 |  | 
 | ECOG performance status |  |  | 
 | 0 | 3 | 7.7 | 
 | 1 | 27 | 69.2 | 
 | 2 | 9 | 23.1 | 
 | Site(s) of metastatic lesion(s)* |  |  | 
 | Lung | 27 | 69.2 | 
 | Liver | 9 | 23.1 | 
 | Lymph node | 15 | 38.5 | 
 | Soft tissue | 3 | 7.7 | 
 | Bone | 24 | 61.5 | 
 | Brain | 3 | 7.7 | 
 | Response to prior anthracyclines |  |  | 
 | Primary resistant | 24 | 61.5 | 
 | Secondary resistant | 15 | 38.5 | 
 | Interval from the cessation of last chemotherapy |  |  | 
 | Median (months) | 4.1 |  | 
 | Range | 1.0 – 11.2 |  | 
 | No. of prior chemotherapy regimens |  |  | 
 | Hormonal therapy (total) | 20 | 51.3 | 
 | 1 | 9 | 23.1 | 
 | 2 | 21 | 53.8 | 
 | 3 or more | 9 | 23.1 | 
 | Characteristics of prior chemotherapy† |  |  | 
 | CMF | 24 |  | 
 | CAF | 15 |  | 
 | FEC | 9 |  | 
 | VE | 21 |  | 
 | High-dose therapy with stem cell rescue | 6 |  | 
 | AT | 3 |  |